{"member_organisations": "", "identification_number": "67826544528-01", "fields_of_interest": "General and Institutional Affairs, Economy, finance and the euro, Humanitarian aid and civil protection, Competition, Employment and Social Affairs, Single market, Regional Policy, Research and innovation, Public Health, Digital economy and society", "head_office_address": "Zieglerstra\u00dfe, 6", "full_time_equivalent_fte": "0,75", "person_with_legal_responsibility": "Gabriel Baertschi", "inter_groups": "", "financial_year_start_date": "01/01/2016", "grants": "15589", "head_office_country": "Germany", "eu_initiatives": "Gr\u00fcnenthal interests in Brussels deal with issues related to health- and pain care, pharmaceuticals, innovation, research and intellectual property.", "organisation_name": "Gr\u00fcnenthal GmbH (Gr\u00fcnenthal)", "belgium_office_post_code": "", "number_of_persons_involved": "2", "procurement": "", "section": "II - In-house lobbyists and trade/business/professional associations", "source": "", "belgium_office_address": "", "subsection": "Companies & groups", "belgium_office_phone": "", "number_of_ep_accredited_persons": "1", "overall_budget_turnover_as_a_range": "", "belgium_office_city": "", "persons_accredited_for_access_to_european_parliament_premises": "Petersen#Gudula Maria", "estimate_of_costs_absolute_amount": "", "registration_date": "14/11/2010", "website_address": "http://www.grunenthal.com", "commission_expert_groups_and_other_similar_entities_european_commission": "NA", "head_office_post_box": "", "head_office_city": "Aachen", "membership": "Gr\u00fcnenthal is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA): http://www.efpia.eu \n \nGr\u00fcnenthal supports the platform the Societal Impact of Pain (SIP). More info can be found here: https://www.sip-platform.eu", "head_office_post_code": "D-52099", "goals__remit": "The Gr\u00fcnenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. \nOur ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a \u20ac2 billion company. \nWe are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation. \nGr\u00fcnenthal is an independent, family-owned company headquartered in Aachen, Germany. We are present in 32 countries with affiliates in Europe, Latin America and the US. Our products are sold in more than 155 countries and approx. 5,500 employees are working for the Gr\u00fcnenthal Group worldwide. In 2016, Gr\u00fcnenthal achieved revenues of approx. \u20ac 1.4 bn. \n \nMore information: www.grunenthal.com", "industry_forums": "", "head_office_phone": "(+49)241 569 0", "level_of_interest": "global", "relevant_communication": "Gr\u00fcnenthal is active on many fronts \u2013 but its primary work (research)\u00a0involvement is in the field of pain relief. For this reason, it is extremely important to us to participate in a wide variety of initiatives in this particular field. \n \nYou find an overview of our initiatives here: https://www.grunenthal.com/grt-web/Grunenthal_Group/Company/Initiatives/en_EN/115200203.jsp", "financial_year_end_date": "01/12/2016", "estimate_of_costs_as_a_range": "300000-399999", "overall_budget_turnover_absolute_amount": "0", "legal_status": "Gesellschaft mit beschr\u00e4nkter Haftung", "person_in_charge_of_eu_relations": "Norbert van Rooij", "customers": "", "belgium_office_post_box": "", "position": "Governmental Affairs and Health Policy"}